Cellular Longevity
Designed to support cellular health and healthy aging.
MOTS-CEpitalonNAD+ Injection
Peptide therapy
Epitalon, Pineal Tetrapeptide Research Therapy
A synthetic tetrapeptide studied in Russia for circadian and longevity outcomes. Western evidence is preliminary. We frame it conservatively.
Epitalon is a synthetic tetrapeptide derived from the bovine pineal extract epithalamin. It sits at the more speculative end of the longevity peptide landscape. The mechanism is not implausible, but the human evidence base comes almost entirely from one Russian research group, lacks Western replication, and the FDA has flagged immunogenicity concerns with repeated dosing.
For patients curious about Epitalon, honest framing of what the science does and does not yet show is the starting point.
What it is
About this therapy
Epitalon (also spelled Epithalon, sequence Ala-Glu-Asp-Gly or AEDG) is a synthetic tetrapeptide developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, derived from bovine pineal gland extract (epithalamin).
In Russia, epithalamin-based preparations have been studied for decades as part of a bioregulator peptide research program, with claims around circadian function, immune modulation, and reduced mortality. The research is substantial in volume. The methodological quality, by modern Western RCT standards, is limited.
In the United States, Epitalon is a research peptide available only through 503A compounding pharmacies under physician prescription. It is not FDA-approved for any indication.
How it works
Mechanism of action
Three mechanisms are most commonly cited. Each carries a specific evidence caveat.
1. Telomerase activation (in vitro evidence). A 2025 study showed that Epitalon, at pharmacological concentrations, upregulates human telomerase reverse transcriptase (hTERT) mRNA expression and extends telomere length in human cell lines. Telomerase activation in cell culture is not equivalent to telomere lengthening in humans. Cancer cells also upregulate telomerase, which is part of why this finding requires careful interpretation.
2. Pineal and circadian modulation (primate model evidence). Russian preclinical work suggests Epitalon modulates melatonin synthesis and circadian rhythms in aged primates. No Western studies have replicated this in humans.
3. Antioxidant and neuroendocrine effects (Russian preclinical). Modulation of IL-2, cholinesterase activity, and oxidative stress markers in Russian animal and observational data.
The critical framing. None of these mechanisms have been confirmed in Western peer-reviewed human RCTs. The telomere data is in vitro. The circadian data is primate-level. Extrapolation to clinical anti-aging effects in humans is speculative.
Conditions and use cases
Where this therapy may fit
Claimed uses are all investigational. None are validated by Western RCTs. Studies suggest preliminary, exploratory signals only.
- General longevity and biological age support, not validated.
- Sleep and circadian dysfunction, pineal-melatonin hypothesis, anecdotal.
- Telomere lengthening, in vitro only.
- Retinal degeneration, small Russian observational series, not independently confirmed.
Expected timeline
What to expect over a care cycle
Week 0 to 2
First cycle response
Vivid dreams and mood shifts are very commonly reported with the first cycle. Subjective sleep changes may emerge.
Week 2 to 4
Cycle completion
Anecdotal reports describe subjective improvements in sleep and energy. Russian protocols typically run 10 to 20 days.
Month 1 to 3
Rest interval
Russian protocols incorporate 7 to 30 day rest periods between cycles. Provider reviews tolerance and immunogenicity considerations.
Month 3 to 6
Repeat cycles
Claimed telomere or biomarker effects are not established in humans by Western standards. Repeat cycles raise immunogenicity questions per the FDA flag.
Stacks that include this
Designed into the Cellular Longevity Stack
Investment and access
How to access this therapy at Genesis
Genesis Longevity therapies are dispensed only after a complimentary consultation and Good Faith Exam. Schedule yours to receive a personalized plan.
Safety
Side effects and contraindications
Reported side effects
Reported in Russian trials and anecdotal compounded use. Limited human data.
- Injection site reactions.
- Headache and lightheadedness.
- Vivid dreams and increased dream recall, very commonly reported, usually mild.
- Mood fluctuations during the first cycle.
- Transient fatigue or drowsiness.
- FDA-flagged risk: immunogenicity, potential for antibody formation with repeated dosing.
Contraindications and patient selection
Absolute contraindications.
- Pregnancy and breastfeeding (no safety data).
- Active malignancy. Telomerase activation raises a theoretical concern regarding cancer cells.
- Autoimmune disease. The FDA has flagged immunogenicity risk with repeated Epitalon dosing.
Relative contraindications.
- Concurrent psychotropic medications, unstudied interactions.
- Children and adolescents, no data.
- Known peptide hypersensitivity.
Frequently asked
Frequently asked questions
The honest answer is unknown. A 2025 in vitro study showed telomere extension in human cell lines at pharmacological concentrations. A Russian observational study reported reduced mortality in an elderly cohort over 12 years, but causality is unproven and bias is substantial. No Western RCT has measured human telomere length change after Epitalon administration.
The existing trials lack modern RCT rigor: adequate sample size, blinding, pre-registered endpoints, and independent replication. No pharmaceutical company has filed a U.S. NDA. The FDA has also flagged immunogenicity concerns with repeated dosing. Until independent Western trials are completed, FDA approval is not possible.
Unknown. Short-term Russian data report no severe adverse events, but the methodology is limited and long-term safety surveillance has not been conducted by modern standards. The FDA's immunogenicity flag adds a specific caution for repeat-cycle protocols.
NAD+ targets cellular energy metabolism (sirtuins, PARPs, mitochondria). Epitalon targets the pineal-circadian axis and a proposed telomerase pathway. MOTS-C targets AMPK and mitochondrial signaling. These are distinct mechanisms with minimal overlap. Combination protocols are plausible in theory, but entirely speculative.
We grade Epitalon as very weak by Western standards. Studies suggest mechanistic plausibility, with limited human data, primarily preclinical and from a single Russian group. Patients pursuing Epitalon at Genesis sign informed consent acknowledging the experimental status.
Sources
Citations & references
- [1]Epitalon, encyclopedic overview. Source
- [2]Alzheimer's Drug Discovery Foundation, Epithalamin and Epithalon Cognitive Vitality research summary. Source
- [3]Innerbody Research, Epitalon Peptide overview, including FDA immunogenicity flag. Source
- [4]Epitalon increases telomere length in human cell lines (in vitro, 2025). PMC12411320.
- [5]Overview of Epitalon, pineal tetrapeptide bioregulator. PubMed 40141333.
- [6]Peptides.org, Epitalon clinical trials and safety summary. Source
Status & disclosures
- FDA status
- Epitalon is a research peptide. It is not FDA-approved. The FDA has flagged immunogenicity concerns with repeated dosing.
- 503A compounding
- Available only through licensed 503A compounding pharmacies under physician prescription, subject to the FDA peptide review.
- Evidence basis
- Primary human data originates from a single Russian research group at the St. Petersburg Institute. No independent Western RCTs confirm efficacy or long-term safety.
- Athletes
- Patients with WADA testing obligations should consult with their sport-governing body before use.
Next step
Curious about a longevity protocol that includes Epitalon?
Schedule a consultation with a Genesis provider in Colorado Springs.
Or keep reading: Or browse the Cellular Longevity stack